ImmunoGen down on Phase III ovarian cancer miss

ImmunoGen Inc. (NASDAQ:IMGN) lost $2.21 (47%) to $2.51 on Friday after reporting that mirvetuximab soravtansine missed the primary endpoint of improving progression-free survival (PFS) in the Phase III FORWARD I trial to treat FOLR1-positive, platinum-resistant ovarian cancer. The antibody-drug conjugate (ADC) links a folate receptor 1 (FOLR1; FR-α; FOLR)-targeting mAb to ImmunoGen’s DM4 cytotoxic agent.

ImmunoGen said it is continuing to evaluate the data to determine next steps for the ADC as monotherapy, based on efficacy signals in a targeted subgroup of patients...